NASDAQ:CMPS

Compass Pathways Stock Insider Trading

Healthcare > Medical - Care Facilities

Buy CMPS

*Your capital is at risk

$12.69

-0.640 (-4.80%)

At Close: Jun 03, 2026

Compass Pathways Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -50.09. In total, the insiders bought 3.17M and sold 11.76M CMPS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-50.09
● Buy	3.17M shares
● Sell	11.76M shares
60% Buy Activity Weak Positive Correlation
Buy Signal Low Confidence May 27, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -50.09. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 27, 2026 Buy	Common Stock J-Other	Tregoning Kathleen	Director	0 Value: $0
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Tregoning Kathleen Director	Director	41 119 Value: $487.3K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Norton David Y Director	Director	21 110 Value: $250.2K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Mcquade Robert Director	Director	21 110 Value: $250.2K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Riley Wayne Joseph Director	Director	21 110 Value: $250.2K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Jonas Jeffrey M Director	Director	21 110 Value: $250.2K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Karydas Daphne Director	Director	21 110 Value: $250.2K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Santini Gino Director	Director	30 158 Value: $357.4K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Gover Justin D. Director	Director	21 110 Value: $250.2K
Mar 26, 2026 Buy	Share Option (Right to Buy) A-Award	Nath Kabir Chief Executive Officer	CEO / President	367 815 Value: $2.07M
Mar 26, 2026 Buy	Ordinary Shares A-Award	Nath Kabir Chief Executive Officer	CEO / President	175 000 Value: $987.0K
Mar 26, 2026 Buy	Share Option (Right to Buy) A-Award	Goodwin Guy Chief Medical Officer	Officer	115 600 Value: $652.0K
Mar 26, 2026 Buy	Share Option (Right to Buy) A-Award	Goodwin Guy Chief Medical Officer	Officer	55 000 Value: $550
Mar 26, 2026 Buy	Share Option (Right to Buy) A-Award	Loxam Teri Chief Financial Officer	C-Suite Officer	157 635 Value: $889.1K
Mar 26, 2026 Buy	Ordinary Shares A-Award	Loxam Teri Chief Financial Officer	C-Suite Officer	75 000 Value: $423.0K
Mar 11, 2026 Sell	Ordinary Shares F-InKind	Loxam Teri Chief Financial Officer	C-Suite Officer	1 781 Value: $12.3K
Mar 11, 2026 Sell	Ordinary Shares F-InKind	Nath Kabir Chief Executive Officer	CEO / President	13 131 Value: $90.5K
Mar 02, 2026 Sell	Ordinary Shares F-InKind	Loxam Teri Chief Financial Officer	C-Suite Officer	4 467 Value: $31.4K
Feb 02, 2026 Sell	Ordinary Shares F-InKind	Nath Kabir Chief Executive Officer	CEO / President	16 181 Value: $107.0K
Oct 29, 2025 Buy	Common Stock J-Other	Jonas Jeffrey M	Director	0 Value: $0
Oct 29, 2025 Buy	Share Option (Right to Buy) A-Award	Jonas Jeffrey M Director	Director	52 000 Value: $329.2K
Aug 01, 2025 Sell	Ordinary Shares F-InKind	Nath Kabir Chief Executive Officer	CEO / President	6 366 Value: $27.6K
Aug 01, 2025 Sell	Ordinary Shares F-InKind	Nath Kabir Chief Executive Officer	CEO / President	6 366 Value: $27.6K
Jul 29, 2025 Buy	Share Option (Right to Buy) A-Award	Gover Justin D. Director	Director	52 000 Value: $223.1K
Jul 29, 2025 Buy	Common Stock J-Other	Gover Justin D.	Director	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COMPASS PATHWAYS PLC

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in Augu...

Read Full Profile Here